German Insurance Stock News

XTRA:SRT3
XTRA:SRT3Life Sciences

Sartorius Q4 Margin Miss Shifts Focus To Earnings Quality And Mix

Sartorius (XTRA:SRT3) reported Q4 results that missed expectations, with pressure on margins. Management issued cautious guidance, highlighting a focus on margin recovery. The company plans to prioritize higher value product rollouts as part of its response. These updates signal a potential inflection point in how Sartorius balances growth, profitability, and product mix. Sartorius, a supplier of equipment and solutions for the biopharma and life sciences industry, operates within long term...
XTRA:NDA
XTRA:NDAMetals and Mining

Did Strong Q1 Results and Higher Guidance Just Shift Aurubis' (XTRA:NDA) Investment Narrative?

Aurubis AG reported past first-quarter 2025–2026 results with sales of €5,293 million and net income of €322 million, both higher than a year earlier. Building on stronger metal prices, resilient copper demand and effective hedging in copper, gold and silver, Aurubis raised its full-year earnings guidance despite minor delays at the Richmond project. We will now examine how the upgraded full-year earnings guidance shapes Aurubis’ investment narrative and future risk-reward...
XTRA:EVK
XTRA:EVKChemicals

Evonik Industries (XTRA:EVK) Margin Rebound Challenges Cautious Earnings Narratives

Evonik Industries (XTRA:EVK) closed FY 2025 with fourth quarter revenue of €3.4b and EPS of €0.15, while trailing twelve month EPS stood at €1.36 on revenue of €14.1b, giving investors a clear snapshot of the current earnings run rate. Over recent periods, revenue has moved from €3.6b in Q4 2024 to €3.4b in Q4 2025, with quarterly EPS swinging from a loss of €0.33 per share in Q4 2024 to a profit of €0.15 in Q4 2025. This frames a year that mixed a weaker top line with a visibly different...